Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial
Background: The risk of recurrence following ischaemic stroke (IS) or transient ischaemic attack (TIA) is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus. Design: The Triple...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
SAGE
2017
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/38851/ |
| _version_ | 1848795705125109760 |
|---|---|
| author | Bath, Philip M.W. Appleton, Jason P. Beridze, M. Christensen, Hanne Dineen, Robert A. Duley, Lelia England, Timothy J. Heptinstall, Stan James, Marilyn Krishnan, Kailash Markus, H.S. Pocock, Stuart J. Ranta, A. Robinson, Thompson G. Flaherty, Katie Scutt, Polly Venables, G. Woodhouse, Lisa J. Sprigg, Nikola |
| author_facet | Bath, Philip M.W. Appleton, Jason P. Beridze, M. Christensen, Hanne Dineen, Robert A. Duley, Lelia England, Timothy J. Heptinstall, Stan James, Marilyn Krishnan, Kailash Markus, H.S. Pocock, Stuart J. Ranta, A. Robinson, Thompson G. Flaherty, Katie Scutt, Polly Venables, G. Woodhouse, Lisa J. Sprigg, Nikola |
| author_sort | Bath, Philip M.W. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Background: The risk of recurrence following ischaemic stroke (IS) or transient ischaemic attack (TIA) is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus.
Design: The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial was an international multicentre prospective randomised open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline treatment in acute IS or TIA. The primary outcome was stroke recurrence and its severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events, functional measures (cognition, disability, mood, quality of life) and safety (bleeding, death, serious adverse events). Data are number (%) or mean (standard deviation, SD).
Results: Recruitment ran from April 2009 to March 2016. 3,096 patients were recruited from 106 sites in 4 countries (Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomisation characteristics included: age 69.0 (10.1) years; male 1945 (62.8%); time onset to randomisation 29.4 (11.9) hours; stroke severity (National Institutes for Health Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), TIA 953 (30.8%).
Conclusion: TARDIS was a large trial of intensive/triple antiplatelet therapy in acute IS and TIA, and included participants from four predominantly Caucasian countries who were representative of patients in many western stroke services. |
| first_indexed | 2025-11-14T19:36:20Z |
| format | Article |
| id | nottingham-38851 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T19:36:20Z |
| publishDate | 2017 |
| publisher | SAGE |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-388512020-05-04T18:52:29Z https://eprints.nottingham.ac.uk/38851/ Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial Bath, Philip M.W. Appleton, Jason P. Beridze, M. Christensen, Hanne Dineen, Robert A. Duley, Lelia England, Timothy J. Heptinstall, Stan James, Marilyn Krishnan, Kailash Markus, H.S. Pocock, Stuart J. Ranta, A. Robinson, Thompson G. Flaherty, Katie Scutt, Polly Venables, G. Woodhouse, Lisa J. Sprigg, Nikola Background: The risk of recurrence following ischaemic stroke (IS) or transient ischaemic attack (TIA) is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus. Design: The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial was an international multicentre prospective randomised open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline treatment in acute IS or TIA. The primary outcome was stroke recurrence and its severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events, functional measures (cognition, disability, mood, quality of life) and safety (bleeding, death, serious adverse events). Data are number (%) or mean (standard deviation, SD). Results: Recruitment ran from April 2009 to March 2016. 3,096 patients were recruited from 106 sites in 4 countries (Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomisation characteristics included: age 69.0 (10.1) years; male 1945 (62.8%); time onset to randomisation 29.4 (11.9) hours; stroke severity (National Institutes for Health Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), TIA 953 (30.8%). Conclusion: TARDIS was a large trial of intensive/triple antiplatelet therapy in acute IS and TIA, and included participants from four predominantly Caucasian countries who were representative of patients in many western stroke services. SAGE 2017-07-01 Article PeerReviewed Bath, Philip M.W., Appleton, Jason P., Beridze, M., Christensen, Hanne, Dineen, Robert A., Duley, Lelia, England, Timothy J., Heptinstall, Stan, James, Marilyn, Krishnan, Kailash, Markus, H.S., Pocock, Stuart J., Ranta, A., Robinson, Thompson G., Flaherty, Katie, Scutt, Polly, Venables, G., Woodhouse, Lisa J. and Sprigg, Nikola (2017) Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. International Journal of Stroke, 12 (5). pp. 524-538. ISSN 1747-4949 Acute ischaemic stroke Acute transient ischaemic attack (TIA) Aspirin Bleeding Clopidogrel Dipyridamole Randomised controlled trial http://journals.sagepub.com/doi/10.1177/1747493016677988 doi:10.1177/1747493016677988 doi:10.1177/1747493016677988 |
| spellingShingle | Acute ischaemic stroke Acute transient ischaemic attack (TIA) Aspirin Bleeding Clopidogrel Dipyridamole Randomised controlled trial Bath, Philip M.W. Appleton, Jason P. Beridze, M. Christensen, Hanne Dineen, Robert A. Duley, Lelia England, Timothy J. Heptinstall, Stan James, Marilyn Krishnan, Kailash Markus, H.S. Pocock, Stuart J. Ranta, A. Robinson, Thompson G. Flaherty, Katie Scutt, Polly Venables, G. Woodhouse, Lisa J. Sprigg, Nikola Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial |
| title | Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial |
| title_full | Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial |
| title_fullStr | Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial |
| title_full_unstemmed | Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial |
| title_short | Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial |
| title_sort | baseline characteristics of the 3,096 patients recruited into the 'triple antiplatelets for reducing dependency after ischaemic stroke' (tardis) trial |
| topic | Acute ischaemic stroke Acute transient ischaemic attack (TIA) Aspirin Bleeding Clopidogrel Dipyridamole Randomised controlled trial |
| url | https://eprints.nottingham.ac.uk/38851/ https://eprints.nottingham.ac.uk/38851/ https://eprints.nottingham.ac.uk/38851/ |